Inventor · disambiguated record
Seung Chu
Also filed as: CHU SEUNG · CHU SEUNG Y · CHU SEUNG YUP
52 granted patents·32 pending applications·668 citations·filing 2004–2025
99Inventor score
Top patents by PatentIndex Score
84 records- 0198US10428155B2Trispecific antibodiesXENCOR INC·Filed 2015·Granted Oct 1, 2019·39 cites·5 claims
- 0298US10259887B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2016·Granted Apr 16, 2019·25 cites·25 claims
- 0398US10227410B2Heterodimeric antibodies that bind CD3 and PSMAXENCOR INC·Filed 2016·Granted Mar 12, 2019·36 cites·27 claims
- 0498US9856327B2Heterodimeric antibodies to CD3 X CD123XENCOR INC·Filed 2016·Granted Jan 2, 2018·72 cites·5 claims
- 0598US8063187B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2008·Granted Nov 22, 2011·130 cites·2 claims
- 0697US11472890B2Heterodimeric antibodies that bind ENPP3 and CD3XENCOR INC·Filed 2020·Granted Oct 18, 2022·9 cites·4 claims
- 0797US11225528B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·13 claims
- 0897US10526417B2Heterodimeric antibodies that bind CD3 and CD38XENCOR INC·Filed 2015·Granted Jan 7, 2020·27 cites·15 claims
- 0996US8551485B2Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cellsBERNETT MATTHEW J·Filed 2009·Granted Oct 8, 2013·45 cites·27 claims
- 1096US8524867B2Optimized antibodies that target CD19BERNETT MATTHEW J·Filed 2007·Granted Sep 3, 2013·56 cites·32 claims
- 1195US11623957B2Heterodimeric antibodies that bind CD3 and PSMAXENCOR INC·Filed 2016·Granted Apr 11, 2023·9 cites·28 claims
- 1295US10227411B2Modulation of T cells with bispecific antibodies and FC fusionsXENCOR INC·Filed 2016·Granted Mar 12, 2019·17 cites·7 claims
- 1395US9850320B2Heterodimeric antibodies to CD3 X CD20XENCOR INC·Filed 2016·Granted Dec 26, 2017·13 cites·5 claims
- 1495US9822186B2Bispecific antibodies that bind to CD38 and CD3XENCOR INC·Filed 2015·Granted Nov 21, 2017·17 cites·16 claims
- 1595US9394366B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2012·Granted Jul 19, 2016·16 cites·22 claims
- 1695US9221916B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2014·Granted Dec 29, 2015·12 cites·3 claims
- 1795US8435517B2Compositions and methods for treating IgE-mediated disordersDESJARLAIS JOHN R·Filed 2009·Granted May 7, 2013·26 cites·8 claims
- 1894US10982006B2Heterodimeric antibodies that bind fibroblast activation proteinXENCOR INC·Filed 2019·Granted Apr 20, 2021·8 cites·23 claims
- 1994US9079960B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2012·Granted Jul 14, 2015·12 cites·16 claims
- 2093US9617348B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2013·Granted Apr 11, 2017·11 cites·3 claims
- 2193US9540451B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2013·Granted Jan 10, 2017·8 cites·6 claims
- 2293US9266966B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2014·Granted Feb 23, 2016·8 cites·1 claims
- 2392US12398207B2Heterodimeric antibodies that bind CD3 and CLDN6XENCOR INC·Filed 2024·Granted Aug 26, 2025·1 cites·4 claims
- 2492US11945880B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2021·Granted Apr 2, 2024·1 cites·13 claims
- 2592US11859011B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2021·Granted Jan 2, 2024·1 cites·2 claims
- 2692US11618788B2Optimized antibodies that target CD19XENCOR INC·Filed 2020·Granted Apr 4, 2023·2 cites·16 claims
- 2792US9260523B2Methods and compositions for inhibiting CD32b expressing cellsCHU SEUNG YUP·Filed 2011·Granted Feb 16, 2016·9 cites·1 claims
- 2890US11566080B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2020·Granted Jan 31, 2023·2 cites·12 claims
- 2990US9062117B2Compositions and methods for treating IgE-mediated disordersDESJARLAIS JOHN·Filed 2013·Granted Jun 23, 2015·9 cites·2 claims
- 3089US11447552B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2011·Granted Sep 20, 2022·3 cites·6 claims
- 3188US12359002B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2023·Granted Jul 15, 2025·0 cites·2 claims
- 3288US11352442B2Heterodimeric antibodies that bind CD3 and CD38XENCOR INC·Filed 2019·Granted Jun 7, 2022·2 cites·19 claims
- 3388US9902773B2Methods and compositions for inhibiting CD32b expressing cellsXENCOR INC·Filed 2014·Granted Feb 27, 2018·4 cites·3 claims
- 3488US2025109215A1Heterodimeric antibodies that bind cd3 and tumor antigensXENCOR INC·Filed 2024·Application pending·0 cites
- 3588US2025304724A1Heterodimeric antibodies that bind cd3 and tumor antigensXENCOR INC·Filed 2025·Application pending·0 cites
- 3687US12497457B2Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseasesXENCOR INC·Filed 2022·Granted Dec 16, 2025·0 cites·8 claims
- 3787US2025109214A1Heterodimeric antibodies that bind cd3 and cd38XENCOR INC·Filed 2024·Application pending·0 cites
- 3886US10889653B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2015·Granted Jan 12, 2021·2 cites·4 claims
- 3985US9803020B2Optimized antibodies that target CD19XENCOR INC·Filed 2013·Granted Oct 31, 2017·5 cites·24 claims
- 4085US7973136B2Optimized anti-CD30 antibodiesXENCOR INC·Filed 2006·Granted Jul 5, 2011·7 cites·8 claims
- 4185US2023340144A1Optimized antibodies that target cd19XENCOR INC·Filed 2023·Application pending·0 cites
- 4284US10913803B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2018·Granted Feb 9, 2021·1 cites·11 claims
- 4384US10858451B2Bispecific antibodies that bind to CD38 and CD3XENCOR INC·Filed 2017·Granted Dec 8, 2020·2 cites·20 claims
- 4484US9914778B2Methods and compositions for inhibiting CD32B expressing cellsXENCOR INC·Filed 2014·Granted Mar 13, 2018·2 cites·3 claims
- 4582US11434295B2Methods and compositions for inhibiting CD32B expressing cellsCHU SEUNG YUP·Filed 2011·Granted Sep 6, 2022·1 cites·5 claims
- 4682US9574006B2Optimized anti-CD30 antibodiesLAZAR GREGORY ALAN·Filed 2011·Granted Feb 21, 2017·5 cites·9 claims
- 4782US2021395363A1Methods and compositions for inhibiting cd32b expressing cellsXENCOR INC·Filed 2021·Application pending·0 cites
- 4880US12129309B2Heterodimeric antibodies that bind CD3 and CD38XENCOR INC·Filed 2022·Granted Oct 29, 2024·0 cites·13 claims
- 4979US10626182B2Optimized antibodies that target CD19XENCOR INC·Filed 2017·Granted Apr 21, 2020·1 cites·27 claims
- 5078US11673972B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2020·Granted Jun 13, 2023·0 cites·7 claims
Showing the top 50 of 84 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →